对喹高利特明显耐药的泌乳素瘤对卡麦角林治疗有反应。 - Suppr | 超能文献

Prolactinomas apparently resistant to quinagolide respond to cabergoline therapy.

作者信息

Colao A, Lombardi G

出版信息

J Clin Endocrinol Metab. 1997 Aug;82(8):2756. doi: 10.1210/jcem.82.8.4178-3.

DOI:10.1210/jcem.82.8.4178-3

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Prolactinomas apparently resistant to quinagolide respond to cabergoline therapy.对喹高利特明显耐药的泌乳素瘤对卡麦角林治疗有反应。

J Clin Endocrinol Metab. 1997 Aug;82(8):2756. doi: 10.1210/jcem.82.8.4178-3.

2

Prolactinomas apparently resistant to quinagolide respond to cabergoline therapy.对喹高利特明显耐药的催乳素瘤对卡麦角林治疗有反应。

J Clin Endocrinol Metab. 1997 Aug;82(8):2755-6. doi: 10.1210/jc.82.8.2755-a.

3

Cabergoline and quinagolide therapy for prolactinomas.卡麦角林和喹高利特治疗泌乳素瘤

Clin Endocrinol (Oxf). 2000 Nov;53(5):549-50. doi: 10.1046/j.1365-2265.2000.01147.x.

4

Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.分泌催乳素和临床无功能垂体腺瘤患者中激素水平及肿瘤大小对喹高利特和卡麦角林的反应：123I-甲氧基苄胺垂体闪烁显像的预测价值

Clin Endocrinol (Oxf). 2000 Apr;52(4):437-45. doi: 10.1046/j.1365-2265.2000.00951.x.

5

The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.两种选择性2型多巴胺受体激动剂喹高利特和卡麦角林在治疗泌乳素瘤中的作用。

Clin Endocrinol (Oxf). 2000 Jul;53(1):53-60. doi: 10.1046/j.1365-2265.2000.01016.x.

6

Prolactinomas and pregnancy.催乳素瘤与妊娠

Clin Endocrinol (Oxf). 2010 Aug;73(2):147-8. doi: 10.1111/j.1365-2265.2010.03823.x. Epub 2010 Jun 9.

7

Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists.多巴胺激动剂治疗的性腺功能减退伴泌乳素瘤男性中的多巴-测试毒性：破坏性的性欲亢进。

Endocrine. 2017 Feb;55(2):618-624. doi: 10.1007/s12020-016-1088-1. Epub 2016 Sep 6.

8

Late development of resistance to bromocriptine in a patient with macroprolactinoma.一例大泌乳素瘤患者对溴隐亭耐药的晚期发生情况。

Horm Res. 1998;49(5):250-3. doi: 10.1159/000023180.

9

Cabergoline, a hopeful medicine for prolactinomas and non-tumoral hyperprolactinemia.卡麦角林，一种治疗催乳素瘤和非肿瘤性高催乳素血症的有前景的药物。

Intern Med. 2001 Sep;40(9):845-6. doi: 10.2169/internalmedicine.40.845.

10

Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine.多巴胺激动剂卡麦角林对不耐受或抵抗溴隐亭的泌乳素瘤患者的影响。

Eur J Endocrinol. 1996 Apr;134(4):454-6. doi: 10.1530/eje.0.1340454.

引用本文的文献

1

Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia.卡麦角林对泌乳素瘤和特发性高泌乳素血症患者瓣膜状态影响的前瞻性长期研究。

Endocrine. 2017 Jan;55(1):239-245. doi: 10.1007/s12020-016-1120-5. Epub 2016 Oct 5.

2

Pharmacological therapy for acromegaly: a critical review.肢端肥大症的药物治疗：一项批判性综述。

Drugs. 2004;64(16):1817-38. doi: 10.2165/00003495-200464160-00007.

3

New medical treatment for acromegaly.

Pituitary. 1999 Jun;2(1):89-92. doi: 10.1023/a:1009930223314.